文献速递艾滋病与性传播感染

长效卡博特韦与利匹韦林治疗药物监测:ANRS-MIE CARLAPOP 研究首报

Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该多中心观察性研究纳入 736 名启动长效卡博特韦/利匹韦林维持治疗的 HIV-1 感染者,分析治疗药物监测所得谷浓度变异及病毒学失败预测因素。结果显示浓度个体间变异显著,BMI≥30 kg/m2 与性别是低谷浓度预测因素,谷浓度不达标尤其合并肥胖增加病毒学失败风险。

要点

  • 长效 CAB/RPV 谷浓度个体间变异显著,第 1/3 月 20%-30% 低于 CAB 1120 ng/mL 或 RPV 32 ng/mL。
  • BMI≥30 kg/m2 和女性性别是第 1 月低谷浓度预测因素,稳态期仅男性性别相关。
  • 至少 2 个危险因素(肥胖、谷浓度不达标)与第 6/12 月病毒学失败显著相关。

核心结论

  • 长效 CAB/RPV 暴露变异显著,谷浓度不达标尤其合并肥胖增加治疗第一年病毒学失败风险,支持临床开展治疗药物监测。

研究设计与样本

  • 多中心观察性研究,纳入 2022 年 1 月至 12 月启动长效 CAB/RPV 维持治疗的 HIV-1 感染者 736 名,共采集 CAB 谷浓度 1674 次、RPV 谷浓度 1687 次。

主要发现

  • CAB 与 RPV 谷浓度个体间变异显著,第 1/3 月 20%-30% 的感染者 CAB 谷浓度<1120 ng/mL 或 RPV 谷浓度<32 ng/mL。
  • 低谷浓度预测因素:第 1 月为 BMI≥30 kg/m2 和女性性别,稳态期为男性性别。
  • 中位随访 12(IQR 9-16)个月,病毒学失败发生率 2.5%。

关键数值与推荐

  • CAB 谷浓度阈值 1120 ng/mL,RPV 谷浓度阈值 32 ng/mL,低于该值定义为谷浓度不达标。

临床怎么用

  • 对接受长效 CAB/RPV 维持治疗的 HIV-1 感染者,尤其肥胖或谷浓度不达标者,可考虑治疗药物监测以识别病毒学失败高风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of pharmacokinetic variability of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) injectable therapy on virological outcomes remains controversial. This study aimed to characterize the variability of CAB and RPV trough concentrations (Ctrough) and to identify the predictors of suboptimal exposure and virologic failure (VF) in a large real-world cohort. METHODS: We conducted a multicenter observational study including people with human immunodeficiency virus type 1 (HIV-1) initiating LA-CAB/RPV as maintenance therapy from January to December 2022, in whom CAB and RPV plasma Ctrough were determined as part of therapeutic drug monitoring (TDM). RESULTS: A total of 1674 CAB and 1687 RPV Ctrough measurements were collected from 736 people with HIV-1 (PWH). Significant interindividual variability in concentrations was observed. At month 1/month 3, 20%-30% of PWH had Ctrough <1120 ng/mL for CAB and 32 ng/mL for RPV. Predictors of lower Ctrough were body mass index (BMI) ≥30 kg/m2 and female sex at month 1, and only male sex at steady state. After a median follow-up of 12 (interquartile range, 9-16) months, VF occurred in 2.5% of PWH. At month 6 and month 12, VF was significantly associated with the presence of at least 2 risk factors (obesity, suboptimal Ctrough) (odds ratio [OR], 4.6, P = .047; OR, 5.15, P = .014), and CD4 nadir (OR, 0.56, P = .008; OR, 0.5, P = .001). CONCLUSIONS: Our large real-world study confirms significant variability in CAB and RPV exposure, with BMI and sex as key predictors of lower Ctrough. Suboptimal CAB and RPV Ctrough, particularly in people with obesity, increases the risk of VF during the first year of treatment, highlighting the usefulness of TDM in clinical practice.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Néant N, Lê MP, Bouchet S, et al. Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study. Clin Infect Dis. 2026. PMID: 40820336. doi:10.1093/cid/ciaf385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。